S-4440-119
Read twice and referred to the Committee on Finance.
Sponsored by Tim Scott (R-SC)
What it does
This bill would authorize federal grants for outreach and recruitment to increase clinical trial participation by underrepresented populations. It would also create new exemptions under the Anti-Kickback Statute and Civil Monetary Penalties Law so that trial sponsors can pay participants' travel, meal, and transportation costs and provide free digital health devices without legal penalty. Additionally, it would allow drug and device manufacturers to cover participants' insurance cost-sharing obligations during trials, and would exclude up to $2,000 per year in clinical trial compensation from a participant's taxable gross income.
Who benefits
Patients from underrepresented populations — including racial and ethnic minorities, rural residents, low-income individuals, and tribal communities — who face financial barriers to clinical trial participation. All clinical trial participants who would receive travel, meal, and cost-sharing assistance. Drug and device manufacturers who would gain clearer legal protection for participant support programs. Community health centers, academic health centers, and rural clinical sites that would receive grant funding. Healthcare workers from underrepresented backgrounds who would receive investigator training. Patients broadly, who may benefit from more diverse trial data producing treatments better validated across demographic groups.
Who is hurt
Federal health care programs (Medicare, Medicaid) that could face increased utilization costs if cost-sharing waivers draw more beneficiaries into trials. Taxpayers who would bear the cost of the new tax exclusion and grant appropriations. Competing clinical trial sites that do not receive grants. Patients who do not qualify as "underrepresented" and may not receive equivalent financial support. Insurers and pharmacy benefit managers who may face indirect cost pressures. The IRS and CMS, which would bear new administrative burdens to implement and monitor the new exemptions and exclusions.
Supporters argue
Supporters argue that clinical trials have long enrolled populations that skew white, male, and affluent, producing drug and device approvals based on data that may not generalize to all patients. They contend that financial barriers — including travel costs, lost wages, and insurance cost-sharing — are a primary reason underrepresented groups decline to participate, and that removing these barriers through targeted grants, legal safe harbors, and a modest tax exclusion is a proportionate, evidence-based response. They point to FDA diversity action plan requirements already in law as evidence that Congress has recognized this gap, and argue this bill provides the financial infrastructure to make those requirements achievable.
Opponents argue
Opponents argue that creating broad Anti-Kickback and False Claims Act exemptions for manufacturer payments to trial participants — even with guardrails — risks being exploited to steer Medicare and Medicaid beneficiaries toward commercially motivated trials rather than the most appropriate care. They contend that allowing manufacturers to pay cost-sharing obligations for their own trial participants creates a financial relationship that could compromise informed consent and independent decision-making, and that the bill's safeguards (e.g., caps on enrollment, prohibition on advertising subsidies) may be difficult to enforce in practice. They also argue the $2,000 tax exclusion, while modest, sets a precedent for tax-preferred compensation that could expand over time.
Constitutional context
Congress has broad authority to regulate clinical trials and modify federal healthcare fraud statutes under the Commerce Clause (Art. I, §8, cl. 3) and the Taxing and Spending Clause (Art. I, §8, cl. 1). The tax exclusion provision is a straightforward exercise of Congress's taxing power. No active constitutional tension is implicated; the bill modifies existing statutory safe harbors rather than creating new mandates on individuals or states.
Checks and balances
The executive branch (HHS Secretary and CMS) gains discretionary authority to award grants and implement new safe harbor rules; Congress retains oversight through the authorization of appropriations structure, and courts retain jurisdiction to review any enforcement actions under the modified Anti-Kickback and False Claims Act provisions.
Historical precedent
The 21st Century Cures Act (2016) similarly sought to modernize clinical trial design and reduce participation barriers, including provisions addressing trial diversity and decentralized trial methods.